Table 3. Phenotypic resistance for 241 MRSA grouped according to their clonal complexes.
CC | CC22 | CC5 | CC398 | CC8 | CC1 | CC9 | ST599 |
total number | n = 92 | n = 58 | n = 72 | n = 16 | n = 1 | n = 1 | n = 1 |
GEN | 3 (3.3%) | 2 (3.4%) | 57 (79.2%) | 7 (43.8%) | 0 | 0 | 0 |
KAN | 3 (3.3%) | 35 (60.3%) | 58 (80.6%) | 14 (87.5%) | 1 | 0 | 0 |
ENR | 90 (97.8%) | 57 (98.2%) | 28 (38.9%) | 14 (87.5%) | 0 | 1 | 0 |
MAR | 90 (97.8%) | 57 (98.2%) | 30 (41.7%) | 14 (87.5%) | 0 | 1 | 0 |
ERY | 32 (34.8%) | 57 (98.2%) | 7 (9.7%) | 3 (18.8%) | 1 | 1 | 0 |
CLI | 34 (37.0%) | 57 (98.2%) | 8 (11.1%) | 2 (12.5%) | 1 | 1 | 0 |
TET | 7 (7.6%) | 1 (1.7%) | 68 (94.4%) | 7 (43.8%) | 1 | 1 | 0 |
NIT | 0 | 0 | 0 | 2 (12.5%) | 0 | 0 | 0 |
CHL | 1 (1.1%) | 0 | 0 | 0 | 0 | 0 | 0 |
SXT | 1 (1.1%) | 1 (1.7%) | 25 (34.7%) | 6 (37.5%) | 0 | 1 | 0 |
Number (n) and percentage (%) of resistant strains according to VITEK®2 system (bioMérieux, Germany).
Abbreviations: GEN: gentamicin, KAN: kanamycin, ENR: enrofloxacin, MAR: marbofloxacin, ERY: erythromycin, CLI: clindamycin, TET: tetracycline, NIT: nitrofurantoin, CHL: chloramphenicol and SXT: trimethoprim- sulfamethoxazole.